Patients who are treated with either transcatheter aortic valve replacement (TAVR) with Evolut or surgical AVR (SAVR) for aortic stenosis (AS) have comparable rates of all-cause death or disabling stroke at 5-years, results from the Evolut Low Risk trial show.